You are here: Home » News-CM » Companies » News
Business Standard

Zydus Cadila receives tentative approval for Mesalamine Suppositories

Capital Market 

From USFDA

Zydus Cadila has received the tentative approval from USFDA to market Mesalamine Suppositories for rectal use, 1000 mg. Mesalamine is used to treat an inflammatory bowel disease, such as ulcerative colitis. It will be produced at the group's Topical Plant at Ahmedabad.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Fri, August 11 2017. 16:16 IST
RECOMMENDED FOR YOU
RECOMMENDED FOR YOU